Navigation Links
GenomeDx Expands Collaboration with Mayo Clinic

SAN DIEGO, April 29, 2013 /PRNewswire/ -- GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property.   The agreement also includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer-term follow up and evaluation of biomarkers. The initial collaboration entered in 2009 led to the development of Decipher™, a transformative genomic test that forecasts risk of metastasis in men with prostate cancer. In addition, GenomeDx announced that five studies evaluating the ability of Decipher to predict metastatic prostate cancer will be featured at the 2013 American Urological Association (AUA) Annual Meeting.

"Access to the Mayo Clinic's comprehensive cohort of samples from patients classified as high risk for metastatic disease and the involvement of Mayo Clinic researchers has been essential to the development of Decipher," said Doug Dolginow , M.D., Chief Executive Officer of GenomeDx. "With Mayo Clinic's large collection of patient samples that had developed metastatic disease, we could reliably identify and validate gene sequences associated with lethal prostate cancer and to create the Decipher test."

Abstracts Related to Decipher at AUA 2013

Podium presentation (May 8, 2013, 8:00-10:00 a.m. Pacific Time)

  • Validation of a genomic classifier that predicts metastatic disease progression in men with high risk pathological features post-prostatectomy, presented by R. Jeffrey Karnes , M.D., associate professor and Vice-Chair in Urology at Mayo Clinic
  • Location: San Diego Convention Center, Room 1

Poster presentations (May 8, 2013, 10:30 a.m.-12:30 p.m. Pacific Time)

  • Comparison of clinical and genomic models for prediction of rapid metastatic disease after radical prostatectomy, Abstract 2229; presented by Ashley Ross , M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
  • Performance of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy, Abstract 2240; presented by Ashley Ross , M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
  • Combined value of genomic biomarkers and CAPRA-S in predicting prostate cancer death in a high-risk surgical cohort, Abstract 2243; presented by Matthew Cooperberg , M.D., assistant professor of urology; epidemiology & biostatistics, University of California, San Francisco
  • Evaluation of a genomic classifier for improved risk stratification in prostate cancer patients with specific adverse pathologies after surgery, Abstract 2230; presented by Doug Dolginow , M.D., CEO GenomeDx Biosciences
  • All posters located in San Diego Convention Center, Room 11

Abstracts for all Decipher studies presented at AUA can be found by searching for the keyword "Decipher" at

About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher™, is a transformative prognostic test that provides a direct measure of the true biological risk of metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, British Columbia. More information is available at

Mayo Clinic has a financial interest in technology licensed to GenomeDx.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millstone Medical Outsourcing Expands Medical Device Distribution Services
2. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
3. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
4. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
5. Western Maryland Health System Expands Use of Versus RTLS to Enhance Staff Safety
6. Compass Diversified Holdings Expands Term Loan Facility by $30 Million and Lowers Interest Rate by 1.25%
7. Phonak Expands Its Quest Platform with New Product Lines
8. Everyday Health Expands Solutions For Pharmaceutical Industry Marketers
9. BioElectronics Expands European Distribution to Malta
10. SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013
11. Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced the addition ... 2019 - Rise in Cardiac Disorders and Growing Awareness among ... offering. Boston scientific and ... and others. --> The market is dominated ... scientific and others. Asia ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 /PRNewswire/ ... --> Juntendo universitetssjukhus ser potential att ... av magnetresonansbilder (MR-bilder) för patienter med ... tecknat ett forskningsavtal med SyntheticMR AB för ... kliniska forskningsprojekt på sjukhuset. Med SyMRI kan ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Representative. As a franchise owner, Somu now offers travelers, value and care based ... packages, private cruise sales, as well as, cabin upgrades and special amenities such ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference ... Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held at ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
Breaking Medicine News(10 mins):